Tubulin-Binding Upconversion Nanoparticles for Breast-Cancer Imaging and Therapy

用于乳腺癌成像和治疗的微管蛋白结合上转换纳米颗粒

基本信息

  • 批准号:
    8507732
  • 负责人:
  • 金额:
    $ 21.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-15 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Normal cell division needs the formation of a mitotic spindle apparatus, which is directly related to microtubule (MT) assembly. Thus, if the MT assembly is inhibited by tubulin-binding agents, the mitotic spindle functions will be perturbed, resulting in the inhibition of cell division at the metaphase/anaphase transition of mitosis. Therefore, tubulin-binding agents are anti-cancer drugs that can inhibit cell division by perturbing the MT assembly and cause cancer cell death. However, the current tubulin-binding anti-cancer drugs cannot specifically recognize cancer cells and serve as imaging probes. Our lab has recently used phage display technique to successfully identify two types of peptides: tubulin-binding peptides and SKBR-3 breast cancer cell-targeting/internalizing peptides. Moreover, we have developed expertise in the synthesis of lanthanide ion doped upconversion nanoparticles (UCNPs) and their utilization as cancer cell imaging probes. In contrast to the down-conversion nanoparticles such as the widely used quantum dots (QDs), the UCNPs can be excited by a longer wavelength light such as near infrared (NIR) light (e.g., 980 nm) to emit a shorter wavelength light (e.g., green light). Due to their ability to be excited by NIR light, whic can penetrate cells and tissues relatively deeply, UCNPs can be used for cell/tissue imaging without causing either autofluorescence from or photodamage to the biomolecules, cells and tissues. This project is based on these successes and will conjugate both tubulin-binding and cancer-targeting/internalizing peptides onto the surface of UCNPs. Our hypothesis is that core-shell upconversion nanoparticles (Rare-earth doped ?-NaYF4:Yb,Er upconversion nanocrystal as a core and silica as a shell) with both tubulin-binding and SKBR-3 breast cancer cell- targeting/internalizing peptides conjugated to the surface will (1) recognize the breast cancer cells and be internalized; (2) bind tubulins to interrupt intracellular MT assembly, inhibit cell proliferation and cause cell death in vitro and in vivo; and (3) enable the selective fluorescent imaging of the cancer cells and tumor tissues under NIR excitation. We will carry out two specific aims: (1) Aim 1: Evaluate the in vitro MT assembly in the presence of UCNPs with both tubulin-binding peptides and SKBR-3 cancer cell-targeting/internalizing peptides conjugated to the surface to understand how cell-targeting tubulin-binding UCNPs interrupt MT assembly in vitro. (2) Aim 2: Evaluate in vitro SKBR-3 breast cancer cell proliferation and cell cycle as well as in vitro and in vivo targeted cancer cell imaging and killing after SKBR-3 cells interact with the cell-targeting tubulin-binding UCNPs in vitro or in vivo. This project will advance the targete cancer treatment and diagnosis by developing targeted cancer imaging and therapeutic agents. The cancer-targeting tubulin-binding UCNPs developed in this project are multi-functional theranostic agents that can target and kill cancer cells and at the same time be fluorescently detected and tracked inside the cancer cells and tumor tissues.
描述(申请人提供):正常细胞分裂需要形成有丝分裂纺锤体,这与微管(MT)组装直接相关。因此,如果微管蛋白结合剂抑制MT组装,有丝分裂纺锤体功能将受到干扰,导致有丝分裂中期/后期转变时细胞分裂受到抑制。因此,微管蛋白结合剂是一种抗癌药物,可以通过干扰 MT 组装来抑制细胞分裂并导致癌细胞死亡。然而,目前的微管蛋白结合抗癌药物不能特异性识别癌细胞并用作成像探针。我们实验室最近利用噬菌体展示技术成功鉴定了两种类型的肽:微管蛋白结合肽和SKBR-3乳腺癌细胞靶向/内化肽。此外,我们还开发了稀土离子掺杂上转换纳米颗粒(UCNP)的合成及其作为癌细胞成像探针的应用方面的专业知识。与下转换纳米颗粒(例如广泛使用的量子点(QD))相比,UCNP 可以被较长波长的光(例如近红外(NIR)光(例如 980 nm))激发,从而发射较短波长的光(例如,绿灯)。由于它们能够被近红外光激发,从而相对较深地穿透细胞和组织,UCNP 可用于细胞/组织成像,而不会引起生物分子、细胞和组织的自发荧光或光损伤。该项目基于这些成功,并将微管蛋白结合肽和癌症靶向/内化肽结合到 UCNP 的表面。我们的假设是核-壳上转换纳米颗粒(稀土掺杂的 ?-NaYF4:Yb,Er 上转换纳米晶体作为核心,二氧化硅作为壳)与微管蛋白结合和 SKBR-3 乳腺癌细胞靶向/内化肽缀合到达表面会(1)识别乳腺癌细胞并被内化; (2)在体外和体内结合微管蛋白,中断细胞内MT组装,抑制细胞增殖并导致细胞死亡; (3)在近红外激发下能够对癌细胞和肿瘤组织进行选择性荧光成像。我们将实现两个具体目标:(1) 目标 1:在 UCNP 存在的情况下评估体外 MT 组装,其中 UCNP 与微管蛋白结合肽和 SKBR-3 癌细胞靶向/内化肽缀合到表面,以了解细胞如何-靶向微管蛋白结合的 UCNP 会中断体外 MT 的组装。 (2)目标2:评估体外SKBR-3乳腺癌细胞增殖和细胞周期,以及SKBR-3细胞与细胞靶向微管蛋白结合的UCNP体外相互作用后的体外和体内靶向癌细胞成像和杀伤作用或体内。该项目将通过开发靶向癌症成像和治疗剂来推进靶向癌症治疗和诊断。该项目开发的癌症靶向微管蛋白结合UCNP是多功能治疗诊断剂,可以靶向并杀死癌细胞,同时在癌细胞和肿瘤组织内进行荧光检测和追踪。

项目成果

期刊论文数量(27)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Theoretical Investigation of Optical Detection and Recognition of Single Biological Molecules Using Coherent Dynamics of Exciton-Plasmon Coupling.
利用激子-等离子体耦合相干动力学对单个生物分子进行光学检测和识别的理论研究。
Tuning molecular weights of Bombyx mori (B. mori) silk sericin to modify its assembly structures and materials formation.
调节家蚕 (B. mori) 丝胶的分子量以改变其组装结构和材料形成。
  • DOI:
  • 发表时间:
    2014-08-27
  • 期刊:
  • 影响因子:
    9.5
  • 作者:
    Yang, Mingying;Shuai, Yajun;Zhou, Guanshan;Mandal, Namita;Zhu, Liangjun;Mao, Chuanbin
  • 通讯作者:
    Mao, Chuanbin
Stable biofunctionalization of hydroxyapatite (HA) surfaces by HA-binding/osteogenic modular peptides for inducing osteogenic differentiation of mesenchymal stem cells.
通过 HA 结合/成骨模块肽对羟基磷灰石 (HA) 表面进行稳定的生物功能化,用于诱导间充质干细胞的成骨分化。
  • DOI:
    10.1039/c4bm00164h
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    Polini A;Wang J;Bai H;Zhu Y;Tomsia AP;Mao C
  • 通讯作者:
    Mao C
Toward a Molecular Understanding of the Antibacterial Mechanism of Copper-Bearing Titanium Alloys against Staphylococcus aureus.
含铜钛合金对金黄色葡萄球菌抗菌机制的分子理解。
  • DOI:
  • 发表时间:
    2016-03-09
  • 期刊:
  • 影响因子:
    10
  • 作者:
    Li, Mei;Ma, Zheng;Zhu, Ye;Xia, Hong;Yao, Mengyu;Chu, Xiao;Wang, Xiaolan;Yang, Ke;Yang, Mingying;Zhang, Yu;Mao, Chuanbin
  • 通讯作者:
    Mao, Chuanbin
Nontoxic virus nanofibers improve the detection sensitivity for the anti-p53 antibody, a biomarker in cancer patients.
无毒病毒纳米纤维提高了抗 p53 抗体(癌症患者的生物标志物)的检测灵敏度。
  • DOI:
  • 发表时间:
    2015-11
  • 期刊:
  • 影响因子:
    9.9
  • 作者:
    Pan, Pengtao;Wang, Yicun;Zhu, Ye;Gao, Xiang;Ju, Zhigang;Qiu, Penghe;Wang, Li;Mao, Chuanbin
  • 通讯作者:
    Mao, Chuanbin
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chuanbin Mao其他文献

NIR-induced highly sensitive detection of latent fingermarks by NaYF4:Yb,Er upconversion nanoparticles in a dry powder state.
通过干粉状态的 NaYF4:Yb,Er 上转换纳米颗粒,NIR 诱导对潜在指纹进行高灵敏度检测。
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    9.9
  • 作者:
    Aoyang Yu;Ye Zhu;Penghe Qiu;Chuanbin Mao
  • 通讯作者:
    Chuanbin Mao
Ca2+-induced self-assembly of Bombyx mori silk sericin into a nanofibrous network-like protein matrix for directing controlled nucleation of hydroxylapatite nano-needles
Ca2 诱导家蚕丝丝胶自组装成纳米纤维网络状蛋白质基质,用于指导羟基磷灰石纳米针的受控成核
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    7
  • 作者:
    Yajun Shuai;Jie Wang;Liangjun Zhu;Chuanbin Mao
  • 通讯作者:
    Chuanbin Mao

Chuanbin Mao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chuanbin Mao', 18)}}的其他基金

Virus-based nanoparticles for detecting breast cancer biomarkers
基于病毒的纳米粒子用于检测乳腺癌生物标志物
  • 批准号:
    9265843
  • 财政年份:
    2016
  • 资助金额:
    $ 21.08万
  • 项目类别:
Hiring Non-toxic Virus Nanoparticles to Count Cancer Biomarker Molecules
使用无毒病毒纳米颗粒来计数癌症生物标志物分子
  • 批准号:
    8873755
  • 财政年份:
    2015
  • 资助金额:
    $ 21.08万
  • 项目类别:
Selective tumor inhibition by tumor-homing angiogenesis-suppressing nanofibers
通过肿瘤归巢血管生成抑制纳米纤维选择性抑制肿瘤
  • 批准号:
    9110918
  • 财政年份:
    2015
  • 资助金额:
    $ 21.08万
  • 项目类别:
Selective tumor inhibition by tumor-homing angiogenesis-suppressing nanofibers
通过肿瘤归巢血管生成抑制纳米纤维选择性抑制肿瘤
  • 批准号:
    9110918
  • 财政年份:
    2015
  • 资助金额:
    $ 21.08万
  • 项目类别:
Hiring Non-toxic Virus Nanoparticles to Count Cancer Biomarker Molecules
使用无毒病毒纳米颗粒来计数癌症生物标志物分子
  • 批准号:
    9070724
  • 财政年份:
    2015
  • 资助金额:
    $ 21.08万
  • 项目类别:
Tubulin-Binding Upconversion Nanoparticles for Breast-Cancer Imaging and Therapy
用于乳腺癌成像和治疗的微管蛋白结合上转换纳米颗粒
  • 批准号:
    8386466
  • 财政年份:
    2012
  • 资助金额:
    $ 21.08万
  • 项目类别:
Bone-seeking and cell-targeting non-viral vectors for BMP-2 gene delivery
用于 BMP-2 基因传递的骨寻找和细胞靶向非病毒载体
  • 批准号:
    8136845
  • 财政年份:
    2011
  • 资助金额:
    $ 21.08万
  • 项目类别:
Bone-seeking and cell-targeting non-viral vectors for BMP-2 gene delivery
用于 BMP-2 基因传递的骨寻找和细胞靶向非病毒载体
  • 批准号:
    7895826
  • 财政年份:
    2009
  • 资助金额:
    $ 21.08万
  • 项目类别:
Phage-inspired nanoparticles with genetically tunable target-specificity
具有基因可调靶点特异性的噬菌体纳米颗粒
  • 批准号:
    7737268
  • 财政年份:
    2009
  • 资助金额:
    $ 21.08万
  • 项目类别:
Phage-Mimetic Nanorods for Targeted Breast Cancer Treatment
用于靶向乳腺癌治疗的噬菌体模拟纳米棒
  • 批准号:
    7904784
  • 财政年份:
    2009
  • 资助金额:
    $ 21.08万
  • 项目类别:

相似国自然基金

基于化学蛋白质组学的紫草素增强化疗药抗肿瘤作用靶标研究
  • 批准号:
    82373749
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
共载肿瘤RNA/金银花多糖的外泌体仿生递药系统构建及其归巢于犬乳腺肿瘤微环境的抗肿瘤免疫机理
  • 批准号:
    32373056
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
荷载鞭毛蛋白的载药囊泡激发中性粒细胞抗肿瘤效应及其机制研究
  • 批准号:
    82303724
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
溶酶体靶向聚集性无药抗肿瘤纳米颗粒的研究
  • 批准号:
    52303170
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
光笼型Mcl-1抑制剂前药的构建与光活化靶向抗肿瘤作用研究
  • 批准号:
    82304305
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of PD-L1 Proteolysis-Targeting Chimeras (PROTACs): An Innovative Cancer Drug Discovery Route
PD-L1 蛋白水解靶向嵌合体 (PROTAC) 的开发:创新的癌症药物发现路线
  • 批准号:
    10605616
  • 财政年份:
    2023
  • 资助金额:
    $ 21.08万
  • 项目类别:
Novel Strategies for Treating Biofilm-Forming Pathogens with Phage Therapy
用噬菌体疗法治疗生物膜形成病原体的新策略
  • 批准号:
    10320958
  • 财政年份:
    2021
  • 资助金额:
    $ 21.08万
  • 项目类别:
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells
肿瘤细胞中 DNA 损伤信号的病理重编程
  • 批准号:
    10062976
  • 财政年份:
    2019
  • 资助金额:
    $ 21.08万
  • 项目类别:
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells
肿瘤细胞中 DNA 损伤信号的病理重编程
  • 批准号:
    10530649
  • 财政年份:
    2019
  • 资助金额:
    $ 21.08万
  • 项目类别:
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells
肿瘤细胞中 DNA 损伤信号的病理重编程
  • 批准号:
    10301006
  • 财政年份:
    2019
  • 资助金额:
    $ 21.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了